Lacrisert
NDC Package 25010-805-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Lacrisert is a medication an insert that is placed in your eye to treat dry eyes. Marketed by Aton Pharma, Inc., this product is identified by NDC 25010-805 and is authorized under FDA application NDA018771.

Identification & Billing

NDC Package Code
25010-805-08
Package Description
10 BLISTER PACK in 1 CARTON / 1 PELLET in 1 BLISTER PACK
Product Code
25010-805
11-Digit Billing Format
25010080508

Clinical Specifications

Proprietary Name
Lacrisert
Dosage Form
-
Usage Information
This medication is an insert that is placed in your eye to treat dry eyes. It is usually used when an artificial tears solution is not successful. This medication may also be used to treat certain other eye disorders (keratitis, decreased corneal sensitivity). It works by keeping the eye moist, helping to protect the eye from injury and infection and to decrease symptoms of dry eyes such as burning, itching, and feeling as if something is in the eye.

Regulatory & Marketing

Labeler Name
Aton Pharma, Inc.
FDA Application #
NDA018771
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-01-1981
End Marketing Date
09-21-2016
Listing Expiration
09-21-2016
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (25010-805). Click a package code to view its specific billing and regulatory data.

25010-805-68
60 BLISTER PACK in 1 CARTON / 1 PELLET in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 25010-805-08 identifies a specific commercial package of 10 blister pack in 1 carton / 1 pellet in 1 blister pack of Lacrisert, labeled by Aton Pharma, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aton Pharma, Inc. on June 01, 1981. The current certification is valid through September 21, 2016.

What are the primary indications for this medication?

This medication is an insert that is placed in your eye to treat dry eyes. It is usually used when an artificial tears solution is not successful. This medication may also be used to treat certain other eye disorders (keratitis, decreased corneal sensitivity). It works by keeping the eye moist, helping to protect the eye from injury and infection and to decrease symptoms of dry eyes such as burning, itching, and feeling as if something is in the eye.

How is this Aton Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 25010080508. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
25010-805-08
11-Digit CMS (5-4-2)
25010-0805-08

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.